Biotech is still breaking funding records. A new report by EY provides an interesting analysis of how Biotech is doing, globally and in Europe.
Although 2015 was the best for Biotech yet, but there is a slowdown coming – that’s the gist of EY’s recent report: ‘Beyond borders 2016: Biotech financing‘.
This well-known auditing and strategy company looked into the fundraising, number of IPOs, innovation capital and venture capital raised by Biotechs in the US and Europe, to form a better picture of what’s going on in the industry.
For the second year in a row, the total of the sector’s financing reached unprecedented heights. Biotechs raised close to $71Bn in 2015 – way more than the record $56Bn of 2014.
How’s Europe doing?
The financials in 2015 was a record for Europe too, even if only by a slight increase – especially considering the jump in 2014.
Europe saw an increase in venture capital and follow-on offerings,